Related Experiment Video

Updated: Sep 28, 2025

Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro
09:41

Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro

Published on: March 17, 2023

3.1K

GLP-1 Receptor Agonists and Coronary Arteries: From Mechanisms to Events

Aurélie Pahud de Mortanges1, Eldem Sinaci1, Dante Salvador2,3

  • 1Faculty of Medicine, University of Bern, Bern, Switzerland.

Frontiers in Pharmacology
|April 4, 2022
PubMed

Insights

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) offer cardiovascular protection by influencing atherosclerosis and vasospasms. Clinical evidence supports their role in preventing coronary syndromes and revascularization.

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) improve glycemic control via insulin/glucagon modulation and delayed gastric emptying.
  • Beyond glucose lowering, GLP-1 RAs demonstrate cardiovascular protective effects.
  • The precise mechanisms linking GLP-1 RAs to coronary artery disease (CAD) require further elucidation.

Purpose of the Study:

  • To review mechanisms by which GLP-1 RAs impact coronary events.
  • To summarize clinical evidence on GLP-1 RA effects on coronary syndromes and revascularization.

Main Methods:

  • Literature search of PubMed and Google Scholar for studies on GLP-1 RAs and coronary events.
  • Review of publications for clinical relevance.
  • Synthesis of evidence on mechanistic pathways and clinical outcomes.

Main Results:

  • GLP-1 RAs influence atherosclerosis, epicardial coronary artery vasospasms, and coronary microvasculature.
  • Clinical data indicate GLP-1 RAs can prevent acute and chronic coronary syndromes.
  • Evidence suggests GLP-1 RAs reduce the need for coronary revascularization.

Conclusions:

  • GLP-1 RAs possess multifaceted cardiovascular benefits relevant to CAD.
  • Further research is needed to fully understand the complex interplay between GLP-1 RAs and coronary artery disease.
  • Future studies should address existing literature gaps regarding GLP-1 RA cardiovascular effects.
Keywords:
GLP-1 receptor agonistsacute and chronic coronary syndromesatherosclerosiscoronary artery diseasecoronary microcirculationdiabetes

More Related Videos

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control05:41

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Published on: December 16, 2022

3.7K
Standardized Rat Coronary Ring Preparation and Real-Time Recording of Dynamic Tension Changes Along Vessel Diameter07:53

Standardized Rat Coronary Ring Preparation and Real-Time Recording of Dynamic Tension Changes Along Vessel Diameter

Published on: June 16, 2022

3.4K

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
451
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
6.0K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.0K
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
799
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
62
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
47